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Abstract 
The precise mechanism of severe acute respiratory syndrome (SARS), which is caused by SARS-associated coronavirus (SARS-CoV), is still 
unclear. We generated recombinant vaccinia virus (rVV) LC16m8 strain which simultaneously expresses four structural proteins of SARS-CoV, 
including nucleocapsid (N), membrane (M), envelop (E), spike (S) proteins (rVV-NMES) and reported that old BALB/c mice having prior 
immunization with rVV-NMES develop severe pneumonia similar to those of control mice though rVV-NMES-immunized mice showed lower
pulmonary viral titer than in the control mice. Furthermore, we determined which SARS-CoV structural protein for the prior rVV-immunization is 
responsible for the severe pneumonia after the SARS-CoV infection as observed in the rVV-NMES-immunized mice. Old BALB/c mice were 
inoculated intradermally with rVV that expressed each structural proteins of SARS-CoV (rVV-N, -M, -E, or -S) with or without rVV-S and then 
infected intranasally with SARS-CoV more than 4 weeks later. At 9 days after SARS-CoV infection, the rVV-N-immunized mice show more 
severe pneumonia than in other groups. Furthermore, significant up-regulation of Th1 (IL-2)- and Th2 (IL-4 and IL-5)-bias cytokines and 
down-regulation of anti-inflammatory cytokine (IL-10 and TGF-E) were observed in rVV-N-immunized mice, resulting in the intensive infiltration 
of immunocompetent cells into the lung. In contrast, rVV-S-immunized mice showed only low pulmonary viral tier and slight pneumonia. 
However, the mice having co-immunization with both rVV-N and rVV-S showed severe pneumonia though their pulmonary viral titer was low. 
These results suggest that an excessive host immune response against the N protein of SARS-CoV is involved in severe pneumonia caused by 
SARS-CoV infection. These findings increase our understanding of the pathogenesis of SARS. 
Keywords: Type your keywords here, separated by semicolons ;  
1. Introduction 
From November 2002 to July 2003, an outbreak of severe acute respiratory syndrome (SARS), which originated in China, 
spread worldwide, resulting in 8098 cases with 774 deaths (http://www.who.int/csr/sars/country/en/index.html). Patients with 
SARS usually develop high fever followed by severe clinical symptoms, which include acute respiratory distress syndrome with 
diffuse alveolar damage (DAD), and ultimately die. A novel type of coronavirus, termed SARS-associated coronavirus 
(SARS-CoV), was identified as the etiologic agent of SARS (1-3). Angiotensin-converting enzyme 2 (ACE2) was identified as the 
host receptor for SARS-CoV (4). ACE2 is abundantly expressed in the epithelia of the lung and small intestine and may mediate 
SARS-CoV entry in humans (5). Although intensive investigations rapidly unraveled the sequence of the SARS-CoV genome and 
its receptor in humans, the precise molecular mechanism underlying the development of SARS is not fully understood. 
The possible roles of host anti-SARS-CoV immune responses have been suggested in severe clinical cases. The uncontrolled 
release of immune mediators, called a ‘cytokine storm’, has been implicated in the pathogenesis of SARS. However, the cytokine 
profiles of SARS patient sera do not correlate with the severity of pneumonia because of their diversity. These results might be
related to patient anamnesis. Therefore, the development of animal models for SARS is needed to understand the pathogenesis of 
SARS. Recently, Roberts et al. reported that aged BALB/c mice (older than 12 months) exhibited high and prolonged levels of viral 
replication, signs of clinical symptoms, and histopathologic changes in the lung (6). Aged BALB/c mice represent a conventional
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animal model that mimics the findings in elderly SARS patients, many of whom exhibit severe disease, requiring intensive care and 
ventilation support, as well as increased mortality. 
In the present study, we investigated the pulmonary immune responses and pathologies of intranasally SARS-CoV-infected 
BALB/c mice of more than 6 months of age that were previously immunized with SARS-CoV structural proteins using vaccinia 
virus vectors. 
2. Generation of recombinant vaccinia virus 
We generated plasmid vector (pBMSF) which expresses transgenes under the control of ATI/p7.5 synthetic hybrid promoter for 
homologous recombination into the hemagglutinin (HA) locus of vaccinia virus LC16m8 strain (m8) (7). Briefly, the transgenes 
that encode the SARS-CoV structural proteins were ligated by inserting internal ribosomal entry site (IRES) sequence of hepatitis C 
virus (2a and 1b/2b) fused with the 2A sequence of Foot and Mouth Disease Virus (FMDV) and Thosea asigna virus (TaV) or 
encephalomyocarditis virus (EMCV) by PCR (Fig. 1A). The generated DNA fragment was digested with EcoRI and inserted 
downstream of the ATI/p7.5 hybrid promoter of pBMSF, thereby generating pBMSF-SARS-NMES. The pBMSF-SARS-NMES 
plasmid was linearized with PvuI, and transfected into primary rabbit kidney (PRK) cells that had been infected with m8 at a 
multiplicity of infection (moi) of 10. After 36 h, the virus-cell mixture were harvested by scraping, and frozen at -80ºC until use. 
The resulting HA-negative recombinant viruses were purified as described previously (8), and named m8rVV-NMES. 
Furthermore, recombinant vaccinia virus LC16mO (mO) that expressed the SARS-CoV N, M or E protein with a six-histidine tag 
at the C-terminus was generated (mOrVV-NHis, -MHis, and EHis), as was mO that expressed six-histidine-tagged S protein 
(mOrVV-SHis), as described previously (8). 
3. SARS-CoV challenge experiment 
Female BALB/c mice aged more than the 6 months were used in this study. Four groups of BALB/c mice (n=7-8 per group) 
were inoculated intradermally with either 1 u 107 pfu/body of m8, m8rVV-S or m8rVV-NMES or 70 ȝl of vehicle (MEM without 
FCS). At 7-8 wks post-immunization, the mice were infected intranasally with 1 u 105 TCID50/body of SARS-CoV (20 ȝl/mouse), 
as described previously (9). The mice were sacrificed under anesthesia and the lung, liver, small intestine, and spleen were 
extirpated 2 days and 9 days later. Aliquots of these tissues were frozen immediately at -80oC or fixed with 10% formalin. The 
collected blood was used for the in vitro neutralization assay (8). In addition, BALB/c mice were injected intradermally with 1 
u 107 pfu/body of rVV that expressed each structural protein of SARS-CoV (mOrVV-N, -M, -E, -S) with or without 
LC16mOrVV-S (i.e., LC16mOrVV-N, -M, -E, -S alone or LC16mOrVV-N + S, -M + S, -E + S), and infected with 1 u 105
TCID50/body of SARS-CoV more than 4 wks later. After 2 days and 9 days, mice (n=3-5 per group) were sacrificed 
following blood collection under anesthesia, and their lungs were extirpated. All animal experiments using mice were 
approvedby the Animal ExperimentCommittee at The Institute of Medical Science, University of Tokyo, and were performed in 
accordance with the animal experimentation guidelines of The Institute of Medical Science, University of Tokyo. The SARS-CoV 
titers in the mouse organs were determined as described previously (9). Serial 10-fold dilutions of the supernatants of the lung
homogenates were added to Vero E6 cells seeded on 96-well plates. After 6 days of incubation, the cells were fixed with 10% 
formalin. Viral titer was determined as the 50% endpoint dilution of the homogenate that induced the cytopathic effect. The method 
used for endpoint calculation was that described by Reed and Muench (10). Ten % formalin-fixed lung tissues of the 
SARS-CoV-infected mice were embedded in paraffin. Paraffin block sections (4-ȝm thickness) were stained with hematoxylin and 
eosin (HE staining). We evaluated pulmonary pathology using the histopathologic scoring systems developed by Cimolai et al. 
(11). To measure the levels of cytokine/chemokine mRNA, total RNA samples were extracted from the lungs using the RNeasy 
Mini kit (Qiagen). Quantitative RT-PCR was carried out with TaqMan Gene Expression assays (Applied Biosystems, Foster City, 
CA) using the ABI Prism 7700 and Sequence Detection System software ver. 1.7. The fold-change in copy number of each 
cytokine/chemokine mRNA was revealed using the 2-''Ct method using 18s rRNA as an endogenous calibrator.  
4. Results and Discussion 
Using attenuated vaccinia virus strain LC16 m8 (m8), we generated recombinant vaccinia virus having a 
multicistronic transgene that expresses simultaneously four structural proteins of SARS-CoV (N, M, E, and S proteins). 
The m8rVV-NMES and m8rVV-S were inoculated intradermally on the backs of BALB/c mice at 1 u 107 pfu/body. At 
7-8 wks after this single immunization, the mice were infected intranasally with SARS-CoV at 1 u 105 TCID50/body 
(Fig. 1B). At 9 days after SARS-CoV infection, severe pulmonary inflammation was observed in m8rVV-NMES-immunized 
BALB/c mice (Fig. 1C, D). However, the initial virus titer was significantly lower than those of the control groups, which included 
vehicle- and m8-immunized mice (Fig. 1E). The severity of pulmonary inflammation did not correlate with the virus titer in the 
m8rVV-NMES-immunized mice, in contrast to the correlations observed for the vehicle-, m8-, and m8rVV-S-immunized groups. 
At 9 days post-infection, both the m8rVV-NMES- and m8rVV-S-immunized groups could elicit significantly 
neutralizing antibodies against SARS-CoV than in control groups (data not shown) and alleviate SARS-CoV infection. 
These results suggest that the severe pulmonary inflammation seen in m8rVV-NMES-immunized mice after SARS-CoV infection 
results from host immune responses rather than a direct cytopathic effect of SARS-CoV, since the virus titers for all the group were 
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negligible 9 days after SARS-CoV infection and the virus titer of the m8rVV-NMES-immunized group was significantly 
decreased 2 days post-infection. 
We hypothesized that the severe pulmonary inflammation seen in the m8rVV-NMES-immunized mice resulted from 
the host immune responses to SARS-CoV components expressed by m8rVV-NMES. Therefore, we investigated the 
influence of rVV expressing each structural protein of SARS-CoV (mOrVV-N, -M, -E, and -S) on subsequent intranasal 
infection with SARS-CoV. BALB/c mice were immunized with mOrVV-N, -M, -E, and -S at 1 u 107 pfu/body, and 4 
wks later infected intradermally with 1 u 105 TCID50 of SARS-CoV (Fig. 2A). Consistent with the above results, a 
Figure 1. SARS-CoV challenge to BALB/c mice immunized with m8rVV-NMES or m8rVV-S.  
(A) Construction of recombinant vaccinia virus that expresses four structural proteins of SARS-CoV (m8rVV-NMES). 
DNA fragments that encode the SARS-CoV N, M, E, and S proteins were ligated with the IRES sequence as described in 
Materials and methods. Recombinant mO that expressed the SARS-CoV N, M, E or S protein was also generated 
(mOrVV-NHis, -MHis, -EHis, and -SHis). (B) Four groups of BALB/c mice (n=7-8) were inoculated intradermally with 
m8rVV-NMES, m8rVV-S, m8 or vehicle, and challenged 7-8 wks later with 1 u 105 TCID50/body of SARS-CoV delivered
via the intranasal route. Blood and lung tissues samples were collected at the indicated time-points. (C) Extirpated lung 
tissues were fixed with 10% formalin and embedded in paraffin. Paraffin block sections (4-Pm thickness) were stained with
hematoxylin and eosin (HE staining). (D) The degree of pulmonary inflammation was determined in a blinded fashion on a
subjective 27-point scale (0, minimal inflammation; 26, massive inflammation) as described in Materials and methods.
Each point represents an individual mouse. An asterisk indicates a significant difference. (E) After 2 days and 9 days, the 
titers of SARS-CoV in the lungs of mice in each group (n=3-4) were determined. Virus titers are expressed as log10 TCID50 
per gram of tissue.  
Fumihiko Yasui et al. / Procedia in Vaccinology 2 (2010) 44–50 47
significant reduction of pulmonary virus titer was observed after 2 days in only the mOrVV-S-immunized group (Fig. 
2B). In contrast, immunization with the other SARS-CoV structural proteins, including the N, M, and E proteins, did not 
confer protection against the subsequent SARS-CoV infection. The alleviation of pulmonary inflammation was also 
observed in the mOrVV-S-immunized group (Fig. 2C). Severe infiltration of lymphocytes and thickening of the alveolar 
epithelia were observed in the lung tissues of the mOrVV-N-immunized mice 9 days after SARS-CoV infection (Fig. 2C). The 
pulmonary damage in the mOrVV-N-immunized mice was significantly more severe than that in the mOrVV-S-immunized mice 
(Fig. 2D). However, there were no significant differences among the other groups.  
To confirm the exacerbating effect of N protein immunization, we investigated the pulmonary virus titers and histopathology in 
BALB/c mice that were previously immunized with the combination of mOrVV-N and mOrVV-S (mOrVV-N+S-immunized 
group) 2 days and 9 days after SARS-CoV infection, and compared them to those of all other groups, including the mO-, 
mOrVV-M+S- mOrVV-E+S-, and mOrVV-S-immunized groups. The mOrVV-N+S-immunized group showed significantly 
decreased pulmonary virus titers compared to the mO-immunized group (Fig. 3A). However, the mOrVV-N+S-immunized group 
exhibited as severe pneumonia as the mO-immunized group (Fig. 3B, 3C). In contrast, both the mOrVV-M+S-immunized group 
and the mOrVV-E+S-immunized group were protected against SARS-CoV infection to the same extent as the 
mOrVV-S-immunized group (Fig. 3A-C).  
Figure 2. Identification of SARS-CoV structural protein implicated in severe pulmonary inflammation.  
(A) Five groups of BALB/c mice were inoculated intradermally with mOrVV-N, -M, -E, -S, or mO, and challenged 4 wks
later with 1 u 105 TCID50/body of SARS-CoV via the intranasal route. (B) After 2 days, the titers of SARS-CoV in the 
lungs of three mice in each group were determined. *p<0.05, as compared to the mO-immunized group using the Dunnett
test. (C) Histopathologic findings for all the groups 9 days after SARS-CoV infection. Paraffin block sections (4-Pm
thickness) were subjected to HE staining. (D) The degree of pulmonary inflammation was determined in a blinded fashion
on a subjective 27-point scale (0, minimal inflammation; 26, massive inflammation). Each point represents an individual 
mouse. An asterisk indicates a significant difference.  
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To date, no studies have been was reported regarding SARS patients with severe pneumonia who were previously immunized 
with either SARS-CoV or a highly related species. In contrast, there are several reports of antisera against human coronaviruses
(229E and OC43) and host factor IL-11 cross-reacting with the SARS-CoV antigen (12, 13). Furthermore, the N protein of 
SARS-CoV has been shown to induce both cellular and humoral immune responses (14-16). Taken together, these results raise the 
possibility that a percentage of SARS patients already possess the adaptive immune response elements that can interact with 
SARS-CoV components, including the N protein, and that their adaptive immune response may be involved in the exacerbation of 
pneumonia. The temporal changes in immune response and the pathogenesis after SARS-CoV infection of an animal model that 
had previously been immunized with SARS-CoV components are not well-understood, as almost all the previous studies reported 
only protection within a few days of SARS-CoV infection (17, 18). In the present study, we demonstrate that 
mOrVV-N-immunized mice after SARS-CoV infection exhibit an imbalance between T-cell activation (high expression levels of 
IFN-J, IL-2, IL-4, and IL-5) and subsequent suppression (low expression levels of IL-10 and TGF-E), as well as high-level 
production of proinflammatory cytokines (IL-6 and TNF-D) and chemokines (CCL2, CCL3, and CXCL10) (data not shown). Both 
IL-10 and TGF-E play important roles in suppressing inflammatory responses (19). Thus, the reduced production of both 
anti-inflammatory cytokines in the mOrVV-N-immunized mice after SARS-CoV infection may be related to the severity of the 
pulmonary inflammation in these mice. Feline infectious peritonitis virus (FIPV), which is another member of the coronavirus 
family, exhibits enhanced FIPV infection into monocytes/macrophages through virus-specific antibody binding to the Fc receptors
of these cells, and causes enhanced inflammation (20). It has also been reported for dengue virus that secondary infection with a 
different genotype results in more severe symptoms, including dengue hemorrhagic fever (DHF) and dengue shock syndrome 
Figure 3. Severe pneumonia in BALB/c mice that were previously immunized with the combination of N protein and S protein of
SARS-CoV.  
(A) Five groups of BALB/c mice were inoculated intradermally with the combinations of mOrVV-N and mOrVV-S 
(mOrVV-N+S), mOrVV-M and mOrVV-S (mOrVV-M+S), mOrVV-E and mOrVV-S (mOrVV-E+S), mOrVV-S, and mO, and
challenged 7 wks later with 1 u 105 TCID50/body of SARS-CoV via the intranasal route. After 2 days, the titers of SARS-CoV in
the lungs of three to five mice from each group were determined. *p<0.05, **p<0.01 using the Bonferroni test, as compared to the
mO-immunized group. (B) Histopathologic findings for all the groups 9 days after SARS-CoV infection. Paraffin block sections 
(4-Pm thickness) were subjected to HE staining. (C) The degree of pulmonary inflammation was determined in a blinded fashion
on a subjective 27-point scale (0, minimal inflammation; 26, massive inflammation). Each point represents an individual mouse. 
†p<0.05, ††p<0.01, as compared to the mO-immunized group using the Bonferroni test. *p<0.05, **p<0.01, as compared to the 
mOrVV-N + S-immunized group using the Bonferroni test. 
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(DSS). The exacerbation of this symptom is also positively associated with pre-existing antibodies with specificity for dengue virus
(21). In the case of SARS-CoV, antibody-dependent enhancement of infection has not been reported previously. We hypothesized 
that the severe pneumonia observed in mOrVV-N-immunized mice after SARS-CoV infection does not result from 
antibody-dependent enhancement, since the virus titers in the mouse lungs 9 days later were below the detection limit. Deming, et 
al. reported recently the intensive infiltration of eosinophils as well as lymphocytes after SARS-CoV infection of aged BALB/c 
mice previously immunized with the N protein of SARS-CoV (22). The authors speculated that the Th2-biased responses of 
vaccinated hosts after SARS-CoV infection might aggravate pulmonary inflammation, although the main host response remains 
unknown. In contrast, our current data suggest that N protein-immunized mice exhibit activation of both Th1 and Th2 responses 
after SARS-CoV infection. In agreement with our data, Jin et al. have demonstrated that prior immunization with N protein 
generates stronger antigen-specific Th1 and Th2 responses than immunization with M or E protein (23). These results suggest that
further studies, including epitope analysis, are required to reveal the precise mechanism underlying the severe pulmonary 
inflammation that results from SARS-CoV infection of BALB/c mice immunized with the N protein of SARS-CoV.  
In contrast, intradermal immunization of aged BALB/c mice with m8rVV-S at 1 u 107 pfu/body significantly reduced the 
pulmonary virus titer 2 days after SARS-CoV infection (Fig. 1E). Furthermore, the m8rVV-S-immunized group exhibited 
alleviation of the pulmonary histopathology, as compared to both control groups after 9 days (Fig. 1C, D). These results suggest
that the systemic immune responses induced by a single immunization with SARS vaccine successfully protect the animal model 
against intranasal SARS-CoV infection. 
In conclusion, we demonstrate that the immunization of BALB/c mice with the N protein of SARS-CoV causes severe 
pulmonary inflammation upon subsequent SARS-CoV infection, probably via the imbalance created between T-cell activation and 
suppression, as well as by massive proinflammatory cytokine production. These results provide new insights into the mechanisms 
involved in the pathogenesis of SARS and help in the development of safe vaccines. 
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